ClearPoint Neuro is demonstrating accelerating revenue growth, exemplified by 42.9% year-over-year growth in Q1 2026, driven by its medical device portfolio. However, this expansion is critically undermined by a deteriorating profitability structure, with oper...
Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 3, 2026 | -$0.38-32.6% vs -$0.29 | $11M-14.6% vs $13M |
Q2 2026 May 13, 2026 | -$0.32-14.3% vs -$0.28 | $12M+1.3% vs $12M |
Q2 2026 Mar 17, 2026 | -$0.27-22.7% vs -$0.22 | $10M+3.5% vs $10M |
Q4 2025 Nov 6, 2025 | -$0.21-5.0% vs -$0.20 | $9M-14.8% vs $10M |
ClearPoint Neuro (NASDAQ: CLPT) reported second-quarter 2026 revenue growth while outlining a shift in investment priorities toward clinical capacity, preclinical laboratory services and technologies intended to support commercial-scale neuro drug delivery. Total revenue for the three months ended June 30 was $10.9 million, up 18% from $9.2 million in the prior-year period, CFO Danilo D'Alessandro said.
ClearPoint Neuro's second quarter results were poor across the board, with drug delivery disposables an area of particular weakness. Delays in the ramping of preclinical services at ClearPoint's new facility have also contributed to reduced expectations for 2026. There is now regulatory clarity, though, meaning a revenue inflection as AMT-130 is commercialized is now highly likely in 2027/2028.
ClearPoint Neuro, Inc. (CLPT) Q2 2026 Earnings Call Transcript
The headline numbers for ClearPoint Neuro (CLPT) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Benchmark CLPT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for ClearPoint Neuro, Inc. (CLPT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $15.79 | $473.54M | -17.54 | 17.78% | -69.08% | -95.64% | — | |
| $16.67 | $1.93B | -13.66 | 8.28% | -21.25% | -44% | — | |
| $20.98 | $1.55B | 6.36 | 18.52% | 80.56% | 30.03% | — | |
| $103.73 | $180.68B | 27.88 | 5.67% | 13.91% | 12.09% | — | |
| $90.77 | $116.54B | 24.34 | 8.43% | 13.93% | 10.51% | — | |
| $15.67 | $647.68M | -17.81 | 9.46% | -11.48% | -21.01% | — |
ClearPoint Neuro, Inc. (CLPT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
ClearPoint Neuro, Inc. (CLPT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 3, 2026·SEC
May 21, 2026·SEC
May 13, 2026·SEC
Get notified when CLPT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ClearPoint Neuro, Inc. (CLPT) stock FAQ — growth, dividends, profitability & financials explained
ClearPoint Neuro, Inc. (CLPT) reported $42.3M in revenue for fiscal year 2025. This represents a 1007% increase from $3.8M in 2011.
ClearPoint Neuro, Inc. (CLPT) grew revenue by 17.8% over the past year. This is strong growth.
ClearPoint Neuro, Inc. (CLPT) reported a net loss of $34.6M for fiscal year 2025.
ClearPoint Neuro, Inc. (CLPT) has a return on equity (ROE) of -95.6%. Negative ROE indicates the company is unprofitable.
ClearPoint Neuro, Inc. (CLPT) had negative free cash flow of $31.3M in fiscal year 2025, likely due to heavy capital investments.
